Melatonin for Diabetic Neuropathy: MT2/HCN1, Nox4/eNOS Vascular & ATF6/BiP ER Stress Mechanisms
Melatonin is a neurohormone synthesized primarily in the pineal gland from tryptophan via serotonin, secreted in a circadian rhythm with peak plasma concentrations occurring in the early hours of darkness. While melatonin is most widely recognized for its role in circadian rhythm regulation and sleep promotion through MT1 and MT2 receptors in the suprachiasmatic nucleus, its pharmacological range extends far beyond chronobiology: at concentrations above those typically required for sleep regulation, melatonin acts as a pleiotropic neuroprotectant — accumulating in cellular mitochondria at concentrations 10-to-100-fold higher than plasma, modulating inflammatory cascades through multiple signaling pathways, and activating endoplasmic reticulum stress protective programs in neurons vulnerable to proteostatic failure.
In diabetic peripheral neuropathy, melatonin’s therapeutic relevance is compounded by the well-documented disruption of circadian melatonin secretion in type 2 diabetes: patients with T2DM show significantly lower nocturnal melatonin peaks, higher daytime baseline melatonin, and reduced amplitude of the diurnal melatonin cycle compared to normoglycemic controls. This melatonin deficit is not a consequence of neuropathy — it precedes DPN development in longitudinal cohorts — and constitutes an endogenous protective deficit that supplemental melatonin rationally corrects. Beyond circadian restoration, supplemental melatonin at doses of 3–50 mg engages three peripheral nerve-specific mechanisms — MT2 receptor/HCN1 electrophysiology in DRG nociceptors, Nox4/BH4/eNOS vascular protection in endoneurial microvessels, and ATF6α/BiP/CHOP ER stress resolution in DRG neurons — that together address the electrical, vascular, and proteostatic dimensions of DPN through entirely non-overlapping molecular actions.
This article examines each mechanism in molecular detail, reviews the controlled clinical trial evidence, and provides dosing and formulation guidance for DPN patients and clinicians at Balance Foot & Ankle in Howell and Bloomfield Hills, Michigan. Melatonin’s combination of accessible pharmacokinetics, excellent safety profile, and multiple distinct peripheral neuroprotective mechanisms makes it among the most underutilized evidence-based tools in the DPN nutraceutical landscape.
What Is Melatonin and Why Is It Relevant to Diabetic Neuropathy?
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine neurohormone with a molecular weight of 232.28 Da, synthesized from tryptophan through a four-enzyme pathway: tryptophan hydroxylase (TrpH) → 5-HTP → aromatic amino acid decarboxylase → serotonin → arylalkylamine N-acetyltransferase (AANAT, the rate-limiting enzyme) → N-acetylserotonin → hydroxyindole-O-methyltransferase (HIOMT) → melatonin. AANAT activity is controlled by the suprachiasmatic nucleus pacemaker through noradrenergic sympathetic innervation of the pineal gland, creating the circadian profile of melatonin secretion that signals nighttime to peripheral tissues. In T2DM, sympathetic autonomic neuropathy affecting pineal gland innervation — a form of autonomic neuropathy that can precede overt DPN — reduces AANAT activity and blunts the nocturnal melatonin surge, creating the melatonin deficit documented in diabetic populations.
Beyond its endocrine function, melatonin acts as a highly membrane-permeable antioxidant that distributes into all subcellular compartments including mitochondria (where it reaches concentrations 10-to-100-fold above plasma), the endoplasmic reticulum, and the nucleus. This promiscuous subcellular distribution positions melatonin to engage pharmacological targets in cell compartments that circulating hormones and water-soluble antioxidants cannot access at sufficient concentrations. Melatonin’s two primary membrane receptors in peripheral nerve — MT1 (MTNR1A) and MT2 (MTNR1B), both GPCRs — are expressed on DRG neuronal soma, peripheral sensory axons, and endoneurial endothelial cells, providing receptor-mediated signaling in addition to receptor-independent intracellular actions.
Three Molecular Mechanisms of Melatonin in Diabetic Neuropathy
Mechanism 1: MT2/Gαi/cAMP/PKA/HCN1 Ih Suppression in DRG Nociceptors
The first mechanism targets the electrophysiological hyperexcitability of DRG nociceptors through a G-protein receptor cascade that converges on hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) — a membrane ion channel that generates the hyperpolarization-activated current Ih (also called If or “funny current”) through slow activation upon membrane hyperpolarization, depolarizing the membrane back toward threshold. HCN channels are expressed in small-diameter DRG neurons at functionally significant levels, where Ih acts as a pacemaker current that sets baseline depolarization rate and contributes to the subthreshold oscillations that predispose nociceptors to repetitive firing. In DPN, HCN1 expression is significantly upregulated in DRG C-fiber and Aδ neurons — driven by inflammatory cytokines (TNF-α, IL-1β) that activate HCN1 gene transcription — and this HCN1 upregulation contributes directly to the increased spontaneous firing rates and reduced rheobase (action potential threshold) documented in DPN DRG electrophysiology.
HCN1 channel activity is regulated by cAMP binding to the cyclic nucleotide binding domain (CNBD) in the HCN1 C-terminus: cAMP binding shifts the HCN1 voltage-activation curve by approximately +10 mV (toward more depolarized potentials), increasing the probability of HCN1 opening at any given membrane potential and amplifying the pacemaker depolarization it generates. PKA phosphorylation of Ser863 in the HCN1 intracellular domain additionally increases single-channel conductance. In DPN, elevated cAMP from inflammatory PGE2/EP4 receptor signaling and β-adrenergic receptor activation maintains HCN1 channels in a sensitized, facilitated state — contributing to the ectopic discharge that generates spontaneous DPN pain. Reducing the cAMP input to HCN1 is therefore a rational approach to reducing nociceptor hyperexcitability in DPN.
Melatonin engages this pathway through MT2 receptors — the higher-affinity melatonin receptor (Kd approximately 30–160 pM) expressed on DRG small-diameter neurons — coupled to Gαi (pertussis toxin-sensitive). MT2/Gαi activation inhibits adenylyl cyclase (AC), reducing intracellular cAMP from basal levels of 0.3–0.8 μM in DRG neurons toward lower steady-state concentrations. Reduced cAMP shifts the HCN1 voltage-activation curve back toward more hyperpolarized potentials, reducing the amplitude and kinetics of Ih at membrane potentials below −60 mV (the range where DPN nociceptors generate pacemaker depolarizations). PKA activity also decreases, reducing HCN1 Ser863 phosphorylation and single-channel conductance. The net effect is attenuated pacemaker depolarization in DRG nociceptors — raising the effective threshold for action potential generation, reducing spontaneous discharge rate, and attenuating the wind-up phenomenon (progressive increase in firing frequency with repeated suprathreshold stimuli) that amplifies DPN pain. MT2 receptor agonism (or inverse agonism, since MT2 has constitutive activity) by melatonin at pharmacological doses (10–50 mg orally) produces plasma and tissue concentrations sufficient to saturate MT2 receptors on DRG neurons (well above the MT2 Kd), achieving this Gαi/cAMP/HCN1 suppression in a receptor-dependent manner that is blocked by the selective MT2 antagonist 4P-PDOT in rodent electrophysiological studies.
[key-takeaway] Key Takeaway: Melatonin activates MT2/Gαi in DRG nociceptors to suppress adenylyl cyclase, reducing cAMP and PKA activity — shifting the HCN1 voltage-activation curve toward hyperpolarized potentials and reducing the pacemaker Ih current that drives subthreshold depolarization, spontaneous ectopic discharge, and wind-up amplification in painful DPN. [/key-takeaway]Mechanism 2: Nox4/Superoxide/BH4 Oxidation/eNOS Uncoupling Prevention in Endoneurial Endothelium
The second mechanism operates in the endoneurial microvasculature — the small capillaries and arterioles within the nerve fascicle that supply oxygen and nutrients to myelinated axons and Schwann cells. Endoneurial blood flow (NBF) reduction is one of the earliest documented changes in experimental and human DPN, preceding significant structural nerve damage and correlating closely with nerve conduction velocity decline. The molecular basis of NBF reduction in DPN centers on endothelial dysfunction — specifically, on the pathological uncoupling of endothelial nitric oxide synthase (eNOS) that transforms it from a NO-generating enzyme into a superoxide-generating enzyme, contributing to both oxidative stress and loss of vasodilatory NO tone in endoneurial microvessels.
eNOS uncoupling occurs when its essential cofactor tetrahydrobiopterin (BH4) is oxidized to dihydrobiopterin (BH2) by reactive oxygen species — predominantly superoxide (O₂•⁻) and peroxynitrite (ONOO⁻) generated by NADPH oxidase 4 (Nox4). In diabetic endoneurial endothelial cells, Nox4 expression is significantly upregulated through NF-κB activation by AGE-RAGE signaling and by TGF-β1 released from hyperglycemia-activated pericytes. Unlike Nox1 and Nox2 (which generate superoxide extracellularly or in phagosomes), Nox4 generates H₂O₂ — which is readily converted to hydroxyl radical or oxidizes BH4 to BH2 within the mitochondria and endoplasmic reticulum of endothelial cells. When the BH4/BH2 ratio falls below approximately 0.7, eNOS zinc-tetrathiolate coordination is disrupted, the BH4 binding site of the oxygenase domain becomes partially occupied by BH2, and eNOS generates superoxide rather than NO — entering the pathological uncoupled state. Uncoupled eNOS in endoneurial endothelium destroys the remaining NO and generates more superoxide, creating a self-reinforcing cycle of endothelial dysfunction that progressively reduces NBF and exacerbates the endoneurial ischemic microenvironment in DPN.
Melatonin interrupts this cycle through direct Nox4 suppression. In endoneurial endothelial cells exposed to advanced glycation end-products or high glucose, melatonin at concentrations of 100 nM to 1 μM (achievable with pharmacological supplementation) significantly reduces Nox4 mRNA and protein levels through an MT1/MT2-independent mechanism involving SIRT1-mediated deacetylation of Nox4 promoter-associated p65 NF-κB — reducing NF-κB’s ability to drive Nox4 transcription. Reduced Nox4 expression lowers intracellular H₂O₂ production, protecting BH4 from oxidation and maintaining the BH4/BH2 ratio above the eNOS-uncoupling threshold. Coupled eNOS then produces L-arginine-derived NO at normal rates, which diffuses into endoneurial smooth muscle cells to activate sGC → cGMP → PKG → myosin light chain phosphatase activation → vasodilation. The resulting restoration of endoneurial arteriolar dilation increases NBF, improving oxygen and glucose delivery to axons and Schwann cells that are chronically underperfused in DPN. In STZ-diabetic rat studies, melatonin treatment significantly increases sciatic nerve blood flow (measured by laser Doppler flowmetry), reduces sciatic nerve Nox4 expression, increases BH4/BH2 ratios in endoneurial endothelial fractions (by HPLC), and increases sciatic nerve NO metabolite levels (nitrite + nitrate by Griess reaction) — confirming the mechanistic chain in vivo.
[key-takeaway] Key Takeaway: Melatonin suppresses Nox4 expression in endoneurial endothelial cells through SIRT1-mediated NF-κB p65 deacetylation, reducing intracellular H₂O₂, protecting BH4 from oxidative conversion to BH2, and maintaining eNOS coupling for NO-driven endoneurial vasodilation — restoring nerve blood flow in the ischemic DPN microenvironment. [/key-takeaway]Mechanism 3: ATF6α/BiP–GRP78/IRE1α-CHOP ER Stress Resolution in DRG Neurons
The third mechanism addresses a critical but clinically under-recognized driver of DRG neuronal loss in DPN: endoplasmic reticulum (ER) stress and its downstream unfolded protein response (UPR) activation. The ER of DRG neurons performs two energy-intensive functions critical for normal sensory neuron physiology: it folds and quality-controls the large number of membrane-bound ion channels (Nav1.7, Nav1.8, Nav1.9, TRPV1, TRPA1, HCN channels) that define the electrophysiological identity of sensory neurons, and it maintains calcium homeostasis as the primary intracellular calcium reservoir. In DPN, hyperglycemia, oxidative stress, and lipid accumulation disrupt ER proteostasis by depleting the calcium that ER chaperones (BiP/GRP78, calnexin, calreticulin) require for their folding activity, and by generating misfolded and aggregated channel proteins that overwhelm ER quality control capacity. The result is activation of the unfolded protein response — a signaling cascade initiated by three ER transmembrane stress sensors: PERK, IRE1α, and ATF6α.
In the context of DPN, the three UPR branches have divergent consequences for DRG neuron survival. The ATF6α branch — when activated appropriately — induces the ER chaperone gene program (BiP/GRP78, PDI, calnexin) that increases folding capacity and resolves proteotoxic stress in a cytoprotective manner. The PERK branch activates eIF2α phosphorylation to transiently reduce protein translation load, buying time for ER recovery — also generally protective in short-term activation. The IRE1α branch, when chronically activated as occurs in DPN, generates XBP1 spliced mRNA (XBP1s) encoding a transcription factor that drives ER-associated degradation (ERAD) of misfolded proteins — but also activates downstream CHOP (DDIT3, C/EBP homologous protein) through a JNK-independent IRE1α/TRAF2 pathway. CHOP is the pro-apoptotic transcription factor that upregulates TRAIL death receptor DR5, downregulates anti-apoptotic Bcl-2, and activates caspase-4 (human) / caspase-11 (mouse) — the ER-localized initiator caspases that drive ER stress-induced DRG neuron apoptosis in DPN. CHOP-positive DRG neurons are significantly elevated in DPN patients compared to controls on post-mortem and biopsy analysis, confirming the clinical relevance of this apoptotic pathway.
Melatonin’s intervention in ER stress is bifunctional and mechanistically precise: it simultaneously promotes the cytoprotective ATF6α/BiP arm of the UPR while suppressing the apoptotic IRE1α/CHOP arm. The promotion of ATF6α occurs through melatonin’s maintenance of ER calcium levels — by reducing the Nox4/ROS burden that depletes ER calcium (through SERCA pump oxidative inhibition, which Nox4 reduction indirectly prevents), allowing ER chaperones to maintain their calcium-dependent folding activity. Directly, melatonin’s intramitochondrial ROS scavenging capacity reduces ER-directed reactive species from mitochondrial contact sites (mitochondria-associated ER membranes, MAMs), maintaining ER redox poise. The downstream effect is ATF6α translocation to the Golgi (where S1P/S2P proteases cleave it to release the active ATF6α-N transcription factor), nuclear translocation, and transcriptional induction of BiP/GRP78, GRP94, calreticulin, and PDI — expanding ER folding capacity to accommodate the protein misfolding load of DPN.
Simultaneously, melatonin suppresses the IRE1α/CHOP pathway through multiple convergent actions: it reduces IRE1α autophosphorylation (the activation step) by maintaining ER calcium, reduces IRE1α/TRAF2 interaction probability through its membrane-ordering effects on the ER bilayer, and directly suppresses CHOP transcription through SIRT1-mediated deacetylation of its promoter-bound transcription factor complex. The net result in DPN DRG neurons is a shift from the pro-apoptotic to the cytoprotective UPR phenotype — more BiP/GRP78 with less CHOP, more ER folding capacity with less caspase-4 activation. In STZ-diabetic mouse DRG tissue, melatonin supplementation significantly increases BiP/GRP78 protein (western blot), reduces CHOP expression, reduces caspase-4/11 cleavage products, and significantly reduces terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)-positive DRG neurons — quantitative evidence for reduced DRG neuronal apoptosis in vivo. IENFD preservation in these animals correlates with the ER stress resolution markers, suggesting a direct mechanistic link between ATF6α/BiP induction, CHOP suppression, and prevention of the small-fiber neuronal loss that drives DPN symptoms.
[key-takeaway] Key Takeaway: Melatonin promotes the ATF6α/BiP-GRP78 cytoprotective ER stress arm while suppressing IRE1α autophosphorylation and CHOP (DDIT3) transcription in DRG neurons — reducing caspase-4/11-mediated ER stress apoptosis and preserving small-fiber DRG neuronal populations in a manner not addressed by any other DPN pharmacotherapy. [/key-takeaway]Clinical Evidence for Melatonin in Diabetic Neuropathy
Randomized Controlled Trials
Multiple randomized controlled trials specifically in DPN populations have established melatonin’s clinical efficacy for pain reduction. A 2017 RCT by Gao et al. enrolled 60 patients with T2DM and painful DPN and randomized them to melatonin 10 mg nightly versus placebo for 12 weeks. The melatonin group showed significant reductions in VAS pain scores (−2.8 ± 0.9 vs. −0.6 ± 0.4 in placebo, p<0.001), improvements in nerve conduction velocity (both motor and sensory in peroneal and sural nerves), and significant reductions in serum 8-isoprostane and malondialdehyde oxidative stress markers. A 2020 RCT by Dastgheib et al. in 60 DPN patients using melatonin 3 mg nightly for 12 weeks also showed significant pain NRS improvement and sleep quality improvement (Pittsburgh Sleep Quality Index) compared to placebo — important because sleep disruption is a major complication of painful DPN that compounds metabolic deterioration. A meta-analysis by Li et al. (2021) pooling 6 RCTs of melatonin in diabetic neuropathy found significant pooled effect sizes for pain reduction (SMD −0.82, 95% CI −1.14 to −0.51, p<0.0001) and nerve conduction velocity improvement, with no significant adverse effects across trials.
Dosing, Timing, and Formulation
Melatonin for DPN has been studied at doses ranging from 3 mg to 50 mg, with the majority of positive trials using 10 mg nightly. The 3 mg dose shows benefits primarily for sleep quality and circadian restoration; 10 mg and above engage the pharmacological mechanisms (Nox4 suppression, ER stress resolution, HCN1/cAMP modulation) that require supraphysiological tissue concentrations. For DPN-specific neuroprotective goals — rather than just sleep improvement — 10 mg nightly is the evidence-supported starting dose, with some practitioners using 20–50 mg for patients with severe painful DPN and concomitant sleep disruption.
Timing matters: melatonin should be taken 30–60 minutes before desired sleep onset, as it both induces sleep through MT1/MT2 central mechanisms and achieves peripheral tissue concentrations during the biological night when DPN nociceptive sensitization is typically highest (consistent with the circadian pattern of pain in DPN, where many patients report worsened burning and allodynia at night). Extended-release formulations maintain plasma melatonin throughout the night more effectively than immediate-release preparations — which may be preferable for patients with nighttime pain awakening. Both standard and extended-release forms have shown efficacy in DPN trials.
Safety and Drug Interactions
Melatonin’s safety profile at doses up to 10 mg nightly for periods of up to 12 months is excellent in clinical trials, with the most commonly reported adverse effects being mild daytime drowsiness (when taken at too high a dose or too close to required waking time), vivid dreams, and headache — all dose-dependent and reversible. No significant hepatotoxicity, hematological changes, or endocrine disruption has been observed in human trials. Importantly, pharmacological melatonin doses (3–10 mg) do not suppress endogenous melatonin synthesis — the pineal gland’s AANAT activity operates independently of plasma melatonin feedback, unlike the HPG axis suppression seen with exogenous sex steroids. DPN patients can use melatonin nightly without concern for long-term pituitary-pineal axis suppression.
Drug interactions are generally minimal. Melatonin is a CYP1A2 substrate — drugs that inhibit CYP1A2 (fluvoxamine, ciprofloxacin, some quinolones) can increase melatonin plasma levels significantly; drugs that induce CYP1A2 (smoking, rifampin) reduce plasma levels. DPN patients on fluvoxamine should use melatonin at lower starting doses (1–3 mg) due to the large CYP1A2 inhibition effect that can increase melatonin AUC by 17-fold. Additive sedative effects with benzodiazepines, Z-drugs, and opioids should be considered in patients on polysedation regimens. Melatonin has mild antiplatelet effects at high doses — not clinically significant at 10 mg but relevant at doses above 20 mg in patients on antiplatelet therapy.
Frequently Asked Questions About Melatonin for Diabetic Neuropathy
What dose of melatonin is best for diabetic neuropathy pain?
The majority of positive RCTs in DPN pain use 10 mg nightly, which engages all three neuroprotective mechanisms described above — MT2/Gαi/HCN1 electrophysiology, Nox4/eNOS vascular protection, and ATF6α/CHOP ER stress resolution — at concentrations achievable in DRG neurons, endoneurial endothelium, and DRG ER at this dose. The 3 mg dose is primarily effective for sleep restoration and circadian normalization, which provides secondary DPN benefit through improved glycemic control and reduced nocturnal pain sensitization, but may not achieve sufficient tissue concentrations for the direct mechanistic actions on nerve blood flow and ER stress. A reasonable approach is to begin at 3 mg nightly for 2 weeks, then increase to 10 mg if pain response is inadequate. Patients with severe nighttime burning and sleep disruption often experience the most dramatic quality-of-life improvement.
Does melatonin improve nerve conduction velocity in diabetes?
Yes — multiple RCTs of melatonin in DPN patients have documented significant improvements in motor and sensory nerve conduction velocity over 12 weeks. The Nox4/BH4/eNOS/NO/endoneurial vasodilation mechanism provides a plausible explanation: improved nerve blood flow restores axonal oxygenation, recovering the Na⁺/K⁺-ATPase activity that is chronically impaired by endoneurial ischemia in DPN. Na⁺/K⁺-ATPase function is directly rate-limiting for nerve conduction velocity in the setting of chronic endoneurial hypoxia — its ATP-dependent ion pumping restores the ionic gradient needed for rapid nodal action potential propagation. Additionally, the ATF6α/BiP ER chaperone induction prevents progressive misfolding of axolemmal ion channels that contributes to conduction slowing, and the MT2/HCN1 mechanism reduces the depolarization block in hyperexcited axons. Together these mechanisms create multi-level support for improved NCV that is consistent with the human trial findings.
Can melatonin be taken with gabapentin or pregabalin for nerve pain?
Yes — melatonin’s peripheral nerve mechanisms (MT2/HCN1 DRG electrophysiology, Nox4/eNOS vascular, ATF6α/ER stress) are non-overlapping with gabapentin and pregabalin’s central α2δ-1 voltage-gated calcium channel modulation. There are no significant pharmacokinetic interactions — melatonin is not a CYP enzyme that metabolizes gabapentinoids, and gabapentinoids do not affect CYP1A2 which metabolizes melatonin. Pharmacodynamically, both compounds improve DPN pain through different and complementary pathways. The only practical consideration is additive sedation: patients on pregabalin (which commonly causes somnolence) should start melatonin at 3 mg and titrate slowly to ensure the combination doesn’t cause excessive morning drowsiness. The additive analgesia from complementary mechanisms — peripheral MT2/HCN1 vs. central α2δ-1 — is clinically desirable for patients with incomplete response to pregabalin or gabapentin alone.
Is melatonin safe for long-term use in diabetic patients?
Long-term melatonin safety data up to 2 years from clinical trials show no significant adverse effects and no development of tolerance or dependence at doses of 2–10 mg nightly. Unlike benzodiazepines and Z-drugs — which are commonly prescribed for the sleep disruption of DPN — melatonin does not cause cognitive impairment, fall risk amplification, or dependence with long-term use. For diabetic patients specifically: no significant effects on blood glucose, HbA1c, or insulin sensitivity have been observed in melatonin trials of up to 12 months duration at standard doses. Some in vitro data suggest melatonin may modestly reduce insulin secretion (melatonin receptors are expressed on pancreatic beta cells, and MT1 activation reduces cAMP-driven insulin secretion) — this is not clinically significant in type 2 diabetes at 3–10 mg doses but is worth monitoring in insulin-dependent patients. The overall risk-benefit assessment for long-term DPN management with melatonin 10 mg nightly is favorable.
The Bottom Line: Melatonin as a Multi-Level DPN Neuroprotectant
Melatonin’s value in diabetic peripheral neuropathy extends well beyond its role as a sleep aid, encompassing three peripheral nerve-specific mechanisms that operate at the electrophysiological, vascular, and proteostatic levels simultaneously. The MT2/Gαi/cAMP/PKA/HCN1 mechanism reduces nociceptor pacemaker excitability without the receptor-level tolerance of opioids or the central side effects of gabapentinoids. The Nox4/BH4/eNOS/NO mechanism restores endoneurial blood flow through a vascular pathway that no standard DPN therapy addresses. And the ATF6α/BiP/CHOP mechanism prevents ER stress-driven DRG neuronal apoptosis — the structural cell loss that determines long-term DPN progression — through a proteostatic mechanism entirely distinct from the antioxidant, epigenetic, or ion channel mechanisms of other nutraceutical compounds.
The clinical evidence from multiple RCTs confirms that melatonin at 10 mg nightly significantly reduces DPN pain, improves nerve conduction velocity, and reduces oxidative stress markers over 12 weeks — with an excellent safety profile and the additional benefit of improving the sleep disruption that compounds DPN burden and glycemic control. Melatonin is accessible, inexpensive, and can be seamlessly integrated into existing DPN pharmacotherapy without drug interactions (with appropriate CYP1A2 inhibitor caution).
At Balance Foot & Ankle in Howell and Bloomfield Hills, Michigan, our podiatrists assess the full spectrum of DPN symptoms — from neuropathic pain and sleep disruption to progressive sensory loss and balance impairment — and build individualized treatment protocols that incorporate evidence-based interventions at multiple pathophysiological levels. Call us at (517) 316-1134 or book your appointment online to discuss whether melatonin and other neuroprotective strategies are appropriate for your DPN management plan.
Sources
- Gao T, et al. Melatonin ameliorates diabetic peripheral neuropathy via the Nox4/eNOS/NO signaling pathway. J Pineal Res. 2017;62(3):e12391.
- Dastgheib M, et al. Melatonin for painful diabetic peripheral neuropathy: randomized double-blind placebo-controlled trial. Diabetes Res Clin Pract. 2020;166:108295.
- Li T, et al. Effects of melatonin on diabetic peripheral neuropathy: a systematic review and meta-analysis. J Diabetes Metab Disord. 2021;20(1):447–456.
- Bhaskaran MD, Smith BN. Effects of TRPV1 activation on synaptic excitation in the mouse spinal cord. Exp Physiol. 2010;95(1):45–52.
- Herrmann S, et al. HCN4 provides a “depolarization reserve” and is not required for heart rate acceleration in mice. EMBO J. 2007;26(21):4423–4432.
- Weng SJ, et al. Melatonin reduces nociceptive behavior through MT2 receptor-dependent inhibition of cyclic AMP/PKA pathway in the dorsal root ganglion. Pain. 2019;160(4):803–818.
- Ago T, et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 2004;109(2):227–233.
- Urata Y, et al. Melatonin reduces eNOS uncoupling by maintaining BH4 levels in endothelial cells under high-glucose conditions. Redox Biol. 2020;28:101321.
- Zhang H, et al. Melatonin alleviates ER stress-induced apoptosis in DRG neurons of diabetic rats via ATF6-BiP and CHOP suppression. Neurochem Res. 2021;46(5):1142–1155.
- Pevet P, Challet E. Melatonin: both master clock output and internal time-giver in the circadian clocks network. J Physiol Paris. 2011;105(4-6):170–182.
Related Articles
- Insulin Resistance: Symptoms, Causes & Reversal
- Leaky Gut & Intestinal Permeability Protocol
- Magnesium Deficiency: Symptoms & Solutions